Inhibitors of mammalian acetyl-CoA carboxylase

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 3, 2007, Pages 162-180

  Corbett, Jeffrey W ^a   Harwood Jr , James H ^a  

^a PFIZER INC   (United States)

Author keywords

Acetyl CoA carboxylase; Diabetes; Enzyme inhibition; Fatty acid oxidation; Fatty acid synthesis; Heart disease; Metabolic regulation; Metabolic syndrome; Obesity

Indexed keywords

1 BENZYLPIPERIDINE DERIVATIVE; ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE INHIBITOR; ALKENE DERIVATIVE; ANTHRANILIC ACID DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; AVENACIOLIDE; AVENACIOLIDE DERIVATIVE; BENZODIOXEPINE DERIVATIVE; BENZTHIAZOLYLAMIDE DERIVATIVE; BIOTIN DERIVATIVE; BIPIPERIDINYLCARBOXAMIDE DERIVATIVE; BISLACTONE DERIVATIVE; CARDIOVASCULAR AGENT; CP 640186; CURCUMIN; ENZYME INHIBITOR; GLUCOSE; HYDROXYUREA; ISOENZYME; NATURAL PRODUCT; SORAPHEN; SPIRO(CHROMENE 2,1' CYCLOHEXAN) 4(3H) ONE DERIVATIVE; SPIRO(CHROMENE 2,4' PIPERIDIN) 4(3H) ONE DERIVATIVE; SPIROCHROMANONE DERIVATIVE; SULFONAMIDE; THIAZOLE DERIVATIVE; THIOPHENYLAMIDE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CRYSTALLIZATION; DIABETES MELLITUS; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATENT; PHARMACOPHORE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ACETYL-COA CARBOXYLASE; ANIMALS; DIABETES MELLITUS; DRUG DESIGN; ENZYME INHIBITORS; HEART DISEASES; HUMANS; ISOENZYMES; METABOLIC SYNDROME X; MICE; OBESITY; RATS;

EID: 36749065136     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007782418928     Document Type: Article

References (39)

1. For recent reviews discussing acetyl-CoA carboxylase as a potential drug target, see: (a) Harwood HJ Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Cardiovasc Renal 2005; 9: 267-81;
2. (b) Tong L, Harwood HJ Jr. Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J Cell Biochem 2006; 99: 1476-88.
3. Abu-Elheiga L, Matzuk MM, Abo-Hashema KAH, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001; 291: 2613-16.
4. Abu-Elhiga L, Oh W, Kordari P, Wakil SJ. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/ high-carbohydrate diets. Proc Natl Acad Sci USA 2003; 100: 10207-12.
5. Abu-Elheiga L, Matzuk MM, Kordari P, et al. Proc Natl Acad Sci USA 2005; 102: 12011-16.
6. Harada N, Oda Z, Hara Y, et al. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol Cell Biol 2007; 27: 1881-1888.
7. Savage DB, Choi CS, Samuel VT, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006; 116: 817-824.
8. Waldrop GL, Stephens JM. Targeting acetyl-CoA carboxylase for anti-obesity therapy. Curr Med Chem Imun Endoc Metab Agents 2003; 3: 229-34.
9. (a) Devine MD. In: Boeger P, Wakabayashi K, Hirai K. Ed, Herbicide classes in development Berlin, Springer-Verlag. 2002; 103-113;
10. (b) Jin L, Ren T, Xiang W, Chen F. Research development on acetyl-CoA carboxylase inhibitors. Chin J Pest Res 2002; 4: 9-17.
11. Reichenbach H, Höfle G. "Production of Bioactive Secondary Metabolites" in Myxobacteria II (Ed. Martin Dworkin and Dale Kaiser), American Society for Microbiology, (1993); p. 373.
12. Gubler, M., Mizrahi, J.: WO03011867 (2003).
13. Shen Y, Volrath SL, Weatherly SC, Elich TD, Tong L. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol Cell 2004; 16: 881-91.
14. (a) Sato, S., Kajiura, T., Okusa, N., Hayashi, E., Nihei, Y.: WO03094912 (2003);
15. (b) Sato, S., Hayashi, E., Okusa, N.: JP035998 (2005).
16. Wellen, C. W.: WO05113069 (2005).
17. Levert KL, Waldrop GL, Stephens JM. A biotin analog inhibits acetyl-CoA carboxylase activity and adipogenesis. J Biol Chem 2002; 277: 16347-50.
18. (a) Strongin, R. M., Saraiva, M. C., Waldrop, G. L., Amspacher, D. R.: US20016242610 (2001);
19. (b) Waldrop, G. L., Stephens, J. M., Levert, K. L.: US20026485941 ( 2002).
20. Igawa, H., Nishimura, M., Okada, K., Nakamura, T.: JP11171848 (1999).
21. Hiroshi, I., Masahito, N., Keiji, O., Takashi, N.: JP11171847 (1999).
22. Ikawa, H., Nishimura, M., Nakamura, T., Kojima, K., Inaba, J., Kosono, H.: WO0202101 (2002).
23. Ikawa, H., Nishimura, M., Okada, K., Nakamura, T., Inaba, N., Kojima, K., Kosono, H.: US20030191323 (2003).
24. Suzuki, N., Nihei, Y., Ichinose, H., Hatanaka, T., Maezono, K., Ohsumi, K., Kondo, N., Yamamoto, T., Nakanishi, E.: WO03059886 (2003).
25. Gobbi, L. C., Gubler, M., Neidhart, W., Nettekoven, M. H.: WO05048814 (2005).
26. (a) Clark, R. F., Zhang, T., Xin, Z., Liu, G., Wang, Y., Hansen, T.M., Wang, X., Wang, R., Zhang, X., Frevert, E.U., Camp, H.S., Beutel, B.A., Sham, H.L., Gu, Y.G. Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity. Bioorg Med Chem Lett 2006; 16: 6078-81;
27. (b) Gu YG, Weitzberg M, Clark RF, Xu X, Li Q, Zhang T, Hansen TM, Liu G, Xin Z, Wang X, Wang R, McNally T, Camp H, Beutel BA, Sham HL. Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy) thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors. J Med Chem 2006; 49: 3770-3.
28. Xu X, Weitzberg M, Keyes RF, et al. The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: Polar region modifications. Bioorg Med Chem Lett 2007; 17: 1803-807.
29. Clark RF, Zhang T, Wang X, et al. Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: Modulation of isozyme selectivity by incorporation of phenyl ring substituents. Bioorg Med Chem Lett 2007; 17: 1961-65.
30. Gu YG, Weitzberg M, Clark RF, et al. N-{3-[2-(4-Alkoxyphenoxy)thiazol-5-yl]-1-methyl-prop-2-ynyl}carboxy derivatives as acetyl-CoA carboxylase inhibitors - Improvement of cardiovascular and neurological liabilities via structural modifications. J Med Chem 2007; 50: 1078-82.
31. Perry, D.A., Harwood, H.J. Jr.: WO03072197 (2003).
32. Harwood HJ, Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003; 278: 37099-37111.
33. Harwood HJ Jr. Advances in Diabetes Treatment 2005 - Second Annual Conference. IDrugs 2005; 8: 374-377.
34. Zhang H, Yang Z, Shen Y, Tong L. Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase. Science 2003; 299: 2064-67.
35. Zhang H, Tweel B, Li J, Tong L. Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186. Structure 2004; 12: 1683-91.
36. Kamata, M., Fukatsu, K., Yamashita, T., Furuyama, N., Endo, S., Takashima, H.: WO07013691 (2007).
37. Ichinose, H., Nihei, Y., Yamamoto, T., Suzuki, N., Nakanishi, E., Kondo, N.: JP119987 (2005).
38. (a) Yamakawa, T., Jona, H., Niiyama, K., Yamada, K., Iino, T., Ohkubo, M., Shibata, J., Kusunoki, J., Yang, L.: WO07011809 (2007);
39. (b) Yamakawa, T., Jona, H., Niiyama, K., Yamada, K., Iino, T., Ohkubo, M., Imamura, H., Kusunoki, J., Yang, L.: WO07011811 (2007).